| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 97,219 | 99,236 | ||
| General and administrative | 16,673 | 16,555 | ||
| Total operating expenses | 113,892 | 115,791 | ||
| Loss from operations | -113,892 | -115,791 | ||
| Interest income | 8,476 | 6,625 | ||
| Interest expense | 2,904 | 94 | ||
| Other income (expense), net | 279 | -1,597 | ||
| Total other income (expense), net | 5,851 | 4,934 | ||
| Net loss | -108,041 | -110,857 | ||
| Unrealized gains on marketable securities, net | 244 | 11 | ||
| Comprehensive loss | -107,797 | -110,846 | ||
| Net loss per share - basic | -0.76 | -0.97 | ||
| Net loss per share - diluted | -0.76 | -0.97 | ||
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)